Sequential interaction of phenytoin and phenobarbital with fluorouracil

Aiko Tsuda; Akiko Miki; Takeshi Togawa; Hiroki Satoh; Satoko Hori; Yasufumi Sawada

doi:10.5414/CP201677

Sequential interaction of phenytoin and phenobarbital with fluorouracil

Aiko Tsuda, Akiko Miki, Takeshi Togawa, Hiroki Satoh, Satoko Hori, Yasufumi Sawada

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as "probable". Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.

Original language	English
Pages (from-to)	862-866
Number of pages	5
Journal	International Journal of Clinical Pharmacology and Therapeutics
Volume	50
Issue number	12
DOIs	https://doi.org/10.5414/CP201677
Publication status	Published - 2012 Dec 1
Externally published	Yes

Keywords

Adverse event
Drug interaction
Fluorouracil
Phenobarbital
Phenytoin

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.5414/CP201677

Fingerprint Dive into the research topics of 'Sequential interaction of phenytoin and phenobarbital with fluorouracil'. Together they form a unique fingerprint.

Cite this

Tsuda, A., Miki, A., Togawa, T., Satoh, H., Hori, S., & Sawada, Y. (2012). Sequential interaction of phenytoin and phenobarbital with fluorouracil. International Journal of Clinical Pharmacology and Therapeutics, 50(12), 862-866. https://doi.org/10.5414/CP201677

@article{4183254d0af746f0bfa60cf8fca56b9e,

title = "Sequential interaction of phenytoin and phenobarbital with fluorouracil",

abstract = "Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as {"}probable{"}. Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.",

keywords = "Adverse event, Drug interaction, Fluorouracil, Phenobarbital, Phenytoin",

author = "Aiko Tsuda and Akiko Miki and Takeshi Togawa and Hiroki Satoh and Satoko Hori and Yasufumi Sawada",

year = "2012",

month = dec,

day = "1",

doi = "10.5414/CP201677",

language = "English",

volume = "50",

pages = "862--866",

journal = "International Journal of Clinical Pharmacology and Therapeutics",

issn = "0946-1965",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "12",

}

TY - JOUR

T1 - Sequential interaction of phenytoin and phenobarbital with fluorouracil

AU - Tsuda, Aiko

AU - Miki, Akiko

AU - Togawa, Takeshi

AU - Satoh, Hiroki

AU - Hori, Satoko

AU - Sawada, Yasufumi

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as "probable". Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.

AB - Objective: We report a case of sequential interaction of phenytoin (PHT) and phenobarbital (PB) with fluorouracil (5-FU). Case report: A male patient aged 60 under treatment with PHT and PB in which serum concentrations of PHT (32.8 μg/ml) and PB (26.7 μg/ml) increased ∼2-fold after the start of postoperative adjuvant therapy with calcium levofolinate (l-LV) and fluorouracil (5-FU). When the drug interactions of this case evaluated using the Drug Interaction Probability Scale, was assessed as "probable". Discussion: In this case, 5-FU increased PHT, which in turn may have increased the PB concentration, suggesting that when fluoropyrimidine antitumor agents are administered to patients receiving PHT in combination with other drugs, some measures should be taken in consideration of secondary effects of antitumor agents on other drugs that may possibly interact with PHT, including frequent monitoring of blood drug concentration.

KW - Adverse event

KW - Drug interaction

KW - Fluorouracil

KW - Phenobarbital

KW - Phenytoin

UR - http://www.scopus.com/inward/record.url?scp=84870210126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870210126&partnerID=8YFLogxK

U2 - 10.5414/CP201677

DO - 10.5414/CP201677

M3 - Article

C2 - 23006440

AN - SCOPUS:84870210126

VL - 50

SP - 862

EP - 866

JO - International Journal of Clinical Pharmacology and Therapeutics

JF - International Journal of Clinical Pharmacology and Therapeutics

SN - 0946-1965

IS - 12

ER -